Home » Company » SkinBioTherapeutics
SkinBiotherapeutics Plc

SkinBioTherapeutics

  • Profile
  • News
  • Interviews
  • Data

SkinBioTherapeutics Plc (LON:SBTX) is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.

The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.

SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas Skin BioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.

The Microbiome

The microbiome is the genetic material of all the microbes – bacteria, fungi, protozoa and viruses – that live on and inside the human body. The microbiome has essential beneficial functions relevant to supporting life and it is a fundamental component of human physiology. Changes in the microbiome can trigger changes in human cellular activities, resulting in disease or contribute to its progression.

The Human Microbiome

  • The human body has around 10X more bacteria within it, and on it than human cells
  • The collective name for all the genes in all the bacteria is ‘the microbiome’
  • The microbiome consists of around 1000,000 genes – humans have around 23,000
  • The microbiome has huge potential to change how the body functions

Skinbiotix

SkinBioTherapeutics uses lysates (extracts) of probiotic bacteria that have been shown to:

  • Increase the skins barrier integrity by enhancing the formation of multi-protein complexes called ‘tight junctions’. Tight junctions seal the space between adjacent gut cells to prevent the passage of toxins, molecules and ions through these spaces
  • Protect the Skin from infection by outcompeting harmful pathogens
  • Increase the rate of Skin healing in response to injury

SkinBioTherapeutics Board Members

Martin Hunt Non - Executive Chairman
Dr Cath O'Neill - Chief Executive Officer
Doug Quinn - Chief Financial Officer
Stephen O'Hara - Non-Executive Director
Dr Cathy Prescott - Non-Executive Director

Company website for SkinBioTherapeutics

http://www.skinbiotherapeutics.com